| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 135, 93-100, Copyright © 1989 by American Society for Investigative Pathology
REGULAR ARTICLES |
K Nakagami, O Shimazaki, R Sato, Y Komine, S Ohkuma and T Takano
Department of Microbiology and Molecular Pathology, Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan.
The monoclonal antibody EMR1a/212D, which recognizes the extracellular matrix in which lipids are deposited in atherosclerotic lesions, was developed previously. The macromolecule containing the epitope recognized by this antibody was purified from serum of WHHL rabbits, antigenic material similar to that found in serum and atherosclerotic plaques. The antigenic material was not associated with lipoproteins in serum. The antigenic material was purified in a single band by SDS-PAGE followed by DEAE-Sepharose CL-6B column chromatography (Pharmacia, Uppsala, Sweden), EMR1a/212D coupled immunoaffinity column chromatography, and HPLC equipped with a TSK gel G3000SWXL (Toso, Japan) column. The purified antigenic material was a glycoprotein of molecular weight 66 kd. It was remarkably high in glutamic acid and aspartic acid but low in arginine and lysine. It had an isoelectric point of pH from 5.4 to 5.9. It contained 22.2 mg of sugar per 100 mg protein, and sialic acid at least expressed the activity of the epitope because the antigenic activity was decreased by neuraminidase treatment.
This article has been cited by other articles:
![]() |
J. R. Guyton and K. F. Klemp Development of the Lipid-Rich Core in Human Atherosclerosis Arterioscler. Thromb. Vasc. Biol., January 1, 1996; 16(1): 4 - 11. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |